Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs397507444
rs397507444
0.010 GeneticVariation BEFREE 677C>T and 1298A>C genotypes were determined simultaneously by melting curve analyses on liver metastases. 15608557

2004

dbSNP: rs879253942
rs879253942
0.010 GeneticVariation BEFREE Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), methylenetetrahydrofolate reductase polymorphism (677C>T, 1298A>C), thymidylate synthase (TS) activity, dihydropyrimidine dehydrogenase activity, folylpolyglutamate synthase activity, and p53 protein expression. 18676755

2008

dbSNP: rs1217691063
rs1217691063
0.010 GeneticVariation BEFREE 677C>T and 1298A>C genotypes were determined simultaneously by melting curve analyses on liver metastases. 15608557

2004

dbSNP: rs397517096
rs397517096
0.010 GeneticVariation BEFREE L747P (2239-2240 TT>CC) in exon 19 is a rare EGFR mutation that appears to lead to gefitinib resistance and might accelerate liver metastases. 26339441

2015

dbSNP: rs4872077
rs4872077
0.010 GeneticVariation BEFREE A novel germline truncating mutation of DR5/TNFRSF10B was identified, and DR4/TNFRSF10A SNP rs4872077 was associated with the development of liver metastases (p = 0.02). 18590575

2008

dbSNP: rs121434569
rs121434569
0.020 GeneticVariation BEFREE After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel. 28193529

2017

dbSNP: rs104886003
rs104886003
0.010 GeneticVariation BEFREE As a proof of the concept, we present the case of a metastatic patient with a PIK3CA wild-type primary tumor in which the PIK3CA E545K mutation was identified in both the circulating-free DNA obtained from a peripheral blood sample and in the formalin-fixed, paraffin-embedded liver metastasis. 26001593

2015

dbSNP: rs752742313
rs752742313
0.010 GeneticVariation BEFREE As a proof of the concept, we present the case of a metastatic patient with a PIK3CA wild-type primary tumor in which the PIK3CA E545K mutation was identified in both the circulating-free DNA obtained from a peripheral blood sample and in the formalin-fixed, paraffin-embedded liver metastasis. 26001593

2015

dbSNP: rs1057519909
rs1057519909
0.010 GeneticVariation BEFREE Biopsy of a patient's progressing liver metastasis following prolonged response to cetuximab revealed a MEK1(K57T) mutation as a novel mechanism of acquired resistance. 26644315

2016

dbSNP: rs7553007
rs7553007
0.010 GeneticVariation BEFREE Both the CRP SNP rs7553007 and KRAS/BRAF mutations were independent prognostic factors for CRC patients with synchronous liver metastasis. 23755178

2014

dbSNP: rs113488022
rs113488022
0.010 GeneticVariation BEFREE BRAF V600E and SRC mutations were mutually exclusive, and SRC mutation was significantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.016 and P = 0.025, respectively). 30792536

2019

dbSNP: rs121913377
rs121913377
0.010 GeneticVariation BEFREE BRAF V600E and SRC mutations were mutually exclusive, and SRC mutation was significantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.016 and P = 0.025, respectively). 30792536

2019

dbSNP: rs1345316856
rs1345316856
0.010 GeneticVariation BEFREE Cell lines stably expressing mutant PRPK (S250A), knockdown TOPK, knockdown PRPK or knockdown of both TOPK and PRPK significantly inhibited liver metastasis of human HCT116 colon cancer cells in a xenograft mouse model. 28412249

2017

dbSNP: rs121913247
rs121913247
MET
0.010 GeneticVariation BEFREE Finally, a <i>MET</i>ex14 del mutation-positive NSCLC patient who responded to crizotinib but later relapsed, demonstrated a mixed response to glesatinib including reduction in size of a <i>MET</i> Y1230H mutation-positive liver metastasis and concurrent loss of detection of this mutation in plasma DNA.<b>Conclusions:</b> Together, these data demonstrate that glesatinib exhibits a distinct mechanism of target inhibition and can overcome resistance to type I MET inhibitors.<i></i>. 28765324

2017

dbSNP: rs121434569
rs121434569
0.020 GeneticVariation BEFREE First-line gefitinib, longer EGFR TKI treatment duration, male, initial liver metastasis and uncommon EGFR mutations may be independent factors for secondary EGFR T790M mutation. 30485437

2019

dbSNP: rs1057519847
rs1057519847
0.010 GeneticVariation BEFREE However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883). 28549835

2017

dbSNP: rs1057519848
rs1057519848
0.010 GeneticVariation BEFREE However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883). 28549835

2017

dbSNP: rs121434568
rs121434568
0.010 GeneticVariation BEFREE However, patients with EGFR 19del and LM showed marginally significantly shorter OS (P = .0531) and patients with EGFR L858R and LM had OS similar to that of patients without LM (P = .1883). 28549835

2017

dbSNP: rs1052133
rs1052133
0.010 GeneticVariation BEFREE Increased frequency of Ser/Ser genotype of hOGG1 Ser326Cys was found to be associated both with higher grade (p = 0.001, OR: 6.4; 95% CI: 2.69-62.69) and liver metastasis (p = 0.005, OR: 7.5; 95% CI: 0.7-68.36). 21561390

2011

dbSNP: rs121913250
rs121913250
0.010 GeneticVariation BEFREE KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C). 29409955

2018

dbSNP: rs121913530
rs121913530
0.010 GeneticVariation BEFREE KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C). 29409955

2018

dbSNP: rs765433422
rs765433422
0.010 GeneticVariation BEFREE KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which additionally revealed 2 rare PI3KCA mutations (c.1633G>C and c.1645G>C). 29409955

2018

dbSNP: rs2910164
rs2910164
0.010 GeneticVariation BEFREE miR-146a Polymorphism (rs2910164) Predicts Colorectal Cancer Patients' Susceptibility to Liver Metastasis. 27824903

2016

dbSNP: rs75873440
rs75873440
RET
0.010 GeneticVariation BEFREE Moreover, RET p.G533C-expressing cells were able to induce liver metastasis in nude mice. 21834681

2011

dbSNP: rs1057519698
rs1057519698
ALK
0.010 GeneticVariation BEFREE Sequencing analyses of DNA from a liver metastasis biopsy sample and circulating tumor DNA both found the same I1171N ALK kinase domain mutation, known to confer resistance to certain ALK inhibitors. 27565911

2016